Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: A randomized, double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 4, 2004, Pages 437-443

  Homoncik, M ^a   Jilma Stohlawetz, P ^a   Schmid, M ^a   Ferlitsch, A ^a   Peck Radosavljevic, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PADGEM PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; BLEEDING TIME; BLOOD PLATELETS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PLATELET COUNT; RETICULOCYTE COUNT; RETICULOCYTES; THROMBOCYTOPENIA;

EID: 4344564900     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02088.x     Document Type: Article

References (29)

1. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 2936-9.
2. Violi F, Ferro D, Quintarelli C, et al. Clotting abnormalities in chronic liver disease. Dig Dis 1992; 10: 162-72.
3. Rubin MH, Weston MJ, Langley PG, et al. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979; 24: 197-202.
4. Mahal AS, Knauer CM, Gregory PB. Bleeding after liver biopsy. West J Med 1981; 134: 11-4.
5. Boberg KM, Brosstad F, Egeland T, et al. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb Haemost 1999; 81: 378-81.
6. Banares R, Casado M, Rodriguez-Laiz JM, et al. Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding. Am J Gastroenterol 1998; 93: 75-9.
7. Jabbour N, Zajko AB. Orons PD, et al. Transjugular intrahepatic portosystemic shunt in patients with end-stage liver disease: results in 85 patients. Liver Transpl Surg 1996; 2: 139-47.
8. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-89.
9. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
10. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993; 3: 1672-9.
11. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-9.
12. Pirisi M, Fabris C, Soardo G, et al. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994; 21: 376-80.
13. Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992; 42: 668-72.
14. van Geet C, Hauglustaine D, Verresen L, et al. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989; 61: 117-21.
15. Stohlawetz P, Horwath M, Pernerstorfer T, et al. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion 1999; 39: 506-14.
16. Jilma-Stohlawetz P, Homoncik M, Jilma B, et al. High levels of reticulated platelets and thrombopoietin characterize fetal thrombopoiesis. Br J Haematol 2001; 112: 466-8.
17. Rebulla P. Trigger for platelet transfusion. Vox Sang 2000; 78(Suppl. 2): 179-82.
18. Strauss RG. Economy of platelet transfusions from a hospital perspective: pricing predicates practice. Transfusion 2001; 41: 1617-24.
19. Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987; 79: 286-9.
20. Papayannopoulou T, Brice M, Farrer D, Kaushansky K. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol 1996; 24: 660-9.
21. Tsukada J, Misago M, Kikuchi M, et al. The effect of high doses of recombinant human erythropoietin on megakaryocytopoiesis and platelet production in splenectomized mice. Br J Haematol 1990; 76: 260-8.
22. Berridge MV, Fraser JK, Carter JM, Lin FK. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 1988; 72: 970-7.
23. Dessypris E, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988; 72: 2060-2.
24. Cosman D. The hematopoietin receptor superfamily. Cytokine 1993; 5: 95-106.
25. Subramaniam M, Frenette PS, Saffaripour S, et al. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-42.
26. Shore-Lesserson A, Tameshwar A, Marietta DePerio RN, et al. Platelet-activated clotting time does not measure platelet reactivity during cardiac surgery. Anesthesiology 1999; 91: 362-8.
27. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998; 65: 352-8.
28. Wahba A, Rothe G, Lodes H, et al. Effects of extracorporeal circulation and heparin on the phenotype of platelet surface antigens following heart surgery. Thromb Res 2000; 97: 379-86.
29. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 2001; 8: 249-54.